Abingdon, United Kingdom

Michael P Mortimore

Average Co-Inventor Count = 5.5

ph-index = 21

Forward Citations = 918(Granted Patents)

Forward Citations (Not Self Cited) = 824(Sep 21, 2024)

DiyaCoin DiyaCoin 0.83 

Inventors with similar research interests:


Location History:

  • West Bridgford, GB (2001 - 2002)
  • Not, GB (2004)
  • Westbridgefored, GB (2006)
  • Burford, Oxfordshire, GB (2009)
  • Burford Oxforshire, GB (2010)
  • Oxfordshire, GB (2004 - 2012)
  • Abington, GB (2012 - 2013)
  • Abingdon, GB (2003 - 2015)
  • Burford, GB (2004 - 2021)


Years Active: 2001-2021

where 'Filed Patents' based on already Granted Patents

67 patents (USPTO):
3 patents (CIPO):

Title: Innovations and Contributions of Michael P Mortimore

Introduction

Michael P Mortimore is an accomplished inventor based in Abingdon, GB, renowned for his significant contributions to the field of biomedical innovations. With an impressive portfolio of 67 patents, Mortimore's work has influenced numerous medical advancements, particularly in cancer treatment and kinase inhibitors.

Latest Patents

Among his latest patents is the invention concerning GCN2 inhibitors and their uses. This patent provides compounds that inhibit General amino acid Control Non-derepressible 2 kinase (GCN2) and outlines methods for their application in treating various disorders, including cancer. Another notable invention by Mortimore focuses on substituted pyrazines as ATR kinase inhibitors. This patent describes pyrazine compounds that serve as inhibitors of ATR protein kinase, detailing their pharmaceutical compositions and applications in treating various diseases, as well as methods for their preparation and study in biological contexts.

Career Highlights

Throughout his career, Michael P Mortimore has made substantial contributions while working with prominent companies in the pharmaceutical sector, including Vertex Pharmaceuticals, Inc. and AstraZeneca AB. His expertise and innovative thinking have led to significant advancements in drug development and therapeutic applications within these organizations.

Collaborations

Mortimore has collaborated with esteemed colleagues such as Jean-Damien Charrier and Ronald Marcellus Knegtel. These partnerships have fostered the exchange of ideas and contributed to the success of his inventions.

Conclusion

Michael P Mortimore's innovative mindset and dedication to advancing medical science are evident through his extensive patent portfolio and collaborative efforts. His recent developments, particularly in the areas of cancer treatment and kinase inhibition, underscore the vital role he plays in the ongoing quest for effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…